Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.63 |
| ▸ | PI4KA | P42356 | 4/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.60 |
| ▸ | AHCY | P23526 | 4/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166469 | 1.00 | ADORA2A (0.63) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12280365 | 1.00 | ADORA2A (0.63) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8885831 | 0.80 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28984637 | 0.78 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14046406 | 0.77 | ADCY5 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14046400 | 0.77 | ADCY5 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9147328 | 0.75 | ADCY5 (0.64) | ADORA2AAHCYADCY5 | |
| SCHEMBL8660508 | 0.75 | ADCY5 (0.64) | ADORA2AAHCYADCY5 | |
| SCHEMBL9786788 | 0.75 | AHCY (0.47) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL978424 | 0.75 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150988-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | claimed |
| WO-2000047591-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | claimed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| EP-2331543-A1 | 3-DEAZANEPLANOCIN DERIVATIVES | Agency For Science, Technology And Research (SG) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036213-A1 | 3-DEAZANEPLANOCIN DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | ADORA2A 4784/4885PI4KA 1765/4885PI4K2B 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.